{"id":3135,"date":"2015-03-24T07:30:00","date_gmt":"2015-03-24T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/"},"modified":"2015-03-24T07:30:00","modified_gmt":"2015-03-24T07:30:00","slug":"kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/","title":{"rendered":"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL)"},"content":{"rendered":"
\u00c5rsst\u00e4mma i XVIVO Perfusion AB (publ) h\u00e5lls torsdagen den 23 april 2015 kl. 16.00 i bolagets lokaler p\u00e5 M\u00e4ssans gata 10 i G\u00f6teborg. Anm\u00e4lan om deltagande vid st\u00e4mman skall g\u00f6ras senast fredagen den 17 april 2015.<\/strong><\/div>\n<\/p>\n

Aktie\u00e4gare som \u00f6nskar delta i \u00e5rsst\u00e4mman skall anm\u00e4la sitt deltagande till bolaget skriftligen p\u00e5 adress XVIVO Perfusion AB (publ), Box 53015, 400 14 G\u00f6teborg, Att: Catrin Olsson, per telefon 031-788 21 53, per fax 031-788 21 69 eller per e-post catrin.olsson@xvivoperfusion.com. Vid anm\u00e4lan skall aktie\u00e4gare uppge namn, person- eller organisationsnummer (eller motsvarande), adress, telefonnummer, aktieinnehav, uppgift om eventuella bitr\u00e4den, samt i f\u00f6rekommande fall uppgift om st\u00e4llf\u00f6retr\u00e4dare eller ombud. F\u00f6r aktie\u00e4gare som f\u00f6retr\u00e4ds av ombud b\u00f6r en av aktie\u00e4garen undertecknad och daterad fullmakt \u00f6vers\u00e4ndas tillsammans med anm\u00e4lan. Fullmaktsformul\u00e4r finns tillg\u00e4ngligt p\u00e5 www.xvivoperfusion.com. <\/span><\/p>\n<\/p>\n

Aktie\u00e4gare som l\u00e5tit f\u00f6rvaltarregistrera sina aktier genom bank eller annan f\u00f6rvaltare m\u00e5ste tillf\u00e4lligt inregistrera aktierna i eget namn i den av Euroclear Sweden AB f\u00f6rda aktieboken f\u00f6r att f\u00e5 delta i st\u00e4mman. F\u00f6r att denna registrering skall vara inf\u00f6rd i aktieboken fredagen den 17 april 2015 b\u00f6r aktie\u00e4gare i god tid f\u00f6re denna dag beg\u00e4ra att f\u00f6rvaltaren ombes\u00f6rjer omregistrering.<\/span><\/p>\n<\/p>\n

Bilaga: Fullst\u00e4ndig kallelse<\/span><\/p>\n<\/p>\n

G\u00f6teborg 24 mars 2015
XVIVO Perfusion AB (publ)
Styrelsen<\/span><\/p>\n

\n

Fr\u00e5gor h\u00e4nvisas till:<\/span>
Fredrik Mattsson, styrelsens ordf\u00f6rande, telefon 08-614 00 20<\/span>
Christoffer Rosenblad, CFO, telefon 031-788 21 59<\/span><\/p>\n

Informationen l\u00e4mnades f\u00f6r publicering den\u00a024\u00a0mars 2015 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u00c5rsst\u00e4mma i XVIVO Perfusion AB (publ) h\u00e5lls torsdagen den 23 april 2015 kl. 16.00 i bolagets lokaler p\u00e5 M\u00e4ssans gata…<\/p>\n","protected":false},"template":"","class_list":["post-3135","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-notice","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing"],"acf":[],"yoast_head":"\nKALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"\u00c5rsst\u00e4mma i XVIVO Perfusion AB (publ) h\u00e5lls torsdagen den 23 april 2015 kl. 16.00 i bolagets lokaler p\u00e5 M\u00e4ssans gata...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\\\/\",\"name\":\"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-03-24T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/","og_locale":"en_US","og_type":"article","og_title":"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL) - XVIVO","og_description":"\u00c5rsst\u00e4mma i XVIVO Perfusion AB (publ) h\u00e5lls torsdagen den 23 april 2015 kl. 16.00 i bolagets lokaler p\u00e5 M\u00e4ssans gata...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/","name":"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-03-24T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (PUBL)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}